GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Distribution » PT Itama Ranoraya Tbk (ISX:IRRA) » Definitions » Intrinsic Value: Projected FCF

PT Itama Ranoraya Tbk (ISX:IRRA) Intrinsic Value: Projected FCF : Rp0.00 (As of Jun. 13, 2024)


View and export this data going back to 2019. Start your Free Trial

What is PT Itama Ranoraya Tbk Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-06-13), PT Itama Ranoraya Tbk's Intrinsic Value: Projected FCF is Rp0.00. The stock price of PT Itama Ranoraya Tbk is Rp480.00. Therefore, PT Itama Ranoraya Tbk's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for PT Itama Ranoraya Tbk's Intrinsic Value: Projected FCF or its related term are showing as below:

ISX:IRRA's Price-to-Projected-FCF is not ranked *
in the Medical Distribution industry.
Industry Median: 0.95
* Ranked among companies with meaningful Price-to-Projected-FCF only.

PT Itama Ranoraya Tbk Intrinsic Value: Projected FCF Historical Data

The historical data trend for PT Itama Ranoraya Tbk's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PT Itama Ranoraya Tbk Intrinsic Value: Projected FCF Chart

PT Itama Ranoraya Tbk Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Intrinsic Value: Projected FCF
Get a 7-Day Free Trial - - - - -

PT Itama Ranoraya Tbk Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Sep23 Dec23 Mar24
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of PT Itama Ranoraya Tbk's Intrinsic Value: Projected FCF

For the Medical Distribution subindustry, PT Itama Ranoraya Tbk's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PT Itama Ranoraya Tbk's Price-to-Projected-FCF Distribution in the Medical Distribution Industry

For the Medical Distribution industry and Healthcare sector, PT Itama Ranoraya Tbk's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where PT Itama Ranoraya Tbk's Price-to-Projected-FCF falls into.



PT Itama Ranoraya Tbk Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)



PT Itama Ranoraya Tbk  (ISX:IRRA) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

PT Itama Ranoraya Tbk's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=480.00/
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PT Itama Ranoraya Tbk Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of PT Itama Ranoraya Tbk's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


PT Itama Ranoraya Tbk (ISX:IRRA) Business Description

Traded in Other Exchanges
N/A
Address
MT. Haryono Square Lantai 1 Unit 101, Jl. Otto Iskandardinata Raya No. 390, No. 390 Jakarta Timur, Jakarta, IDN, 13330
PT Itama Ranoraya Tbk focuses on the trade and distribution of medical devices. The company distributes medical devices such as Oneject auto disable syringe, Abbott diagnostics, TerumoBCT, Ortho Clinical diagnostics and others. The key revenue generating segments of the company are Sterile Non-Electromedical Medical Equipment and In Vitro Diagnostic product.

PT Itama Ranoraya Tbk (ISX:IRRA) Headlines

No Headlines